EGTX — Egetis Therapeutics AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK1.97bn
- SEK1.78bn
- SEK57.60m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 82.6 | 40.7 | 38.2 | 22.6 | 57.6 |
Cost of Revenue | |||||
Gross Profit | — | 38.8 | 30.4 | 16.3 | 46.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 149 | 218 | 144 | 221 | 382 |
Operating Profit | -66.7 | -177 | -106 | -198 | -325 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -61.4 | -178 | -105 | -194 | -327 |
Provision for Income Taxes | |||||
Net Income After Taxes | -61.4 | -178 | -105 | -194 | -327 |
Net Income Before Extraordinary Items | |||||
Net Income | -61.4 | -178 | -105 | -194 | -327 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -61.4 | -178 | -105 | -194 | -327 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.08 | -2.42 | -0.581 | -0.998 | -1.27 |
Dividends per Share |